622 related articles for article (PubMed ID: 30220457)
1. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M
Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
[TBL] [Abstract][Full Text] [Related]
4. Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma.
Romanchikova N; Trapencieris P
Anticancer Res; 2019 Aug; 39(8):4179-4184. PubMed ID: 31366503
[TBL] [Abstract][Full Text] [Related]
5. Loss of BAP1 function leads to EZH2-dependent transformation.
LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
[TBL] [Abstract][Full Text] [Related]
6. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis.
Lee YY; Mok MT; Kang W; Yang W; Tang W; Wu F; Xu L; Yan M; Yu Z; Lee SD; Tong JHM; Cheung YS; Lai PBS; Yu DY; Wang Q; Wong GLH; Chan AM; Yip KY; To KF; Cheng ASL
Nucleic Acids Res; 2018 Sep; 46(17):8832-8847. PubMed ID: 29992318
[TBL] [Abstract][Full Text] [Related]
7. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
8. Deregulated Polycomb functions in myeloproliferative neoplasms.
Sashida G; Oshima M; Iwama A
Int J Hematol; 2019 Aug; 110(2):170-178. PubMed ID: 30706327
[TBL] [Abstract][Full Text] [Related]
9. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
10. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing.
Nuytten M; Beke L; Van Eynde A; Ceulemans H; Beullens M; Van Hummelen P; Fuks F; Bollen M
Oncogene; 2008 Feb; 27(10):1449-60. PubMed ID: 17724462
[TBL] [Abstract][Full Text] [Related]
11. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
12. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
13. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
[TBL] [Abstract][Full Text] [Related]
14. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.
Sashida G; Iwama A
Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
[TBL] [Abstract][Full Text] [Related]
15. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors.
Ishi Y; Zhang Y; Zhang A; Sasaki T; Piunti A; Suri A; Watanabe J; Abe K; He X; Katagi H; Bhalla P; Natsumeda M; Zou L; Shilatifard A; Hashizume R
Mol Cancer Ther; 2022 May; 21(5):715-726. PubMed ID: 35247919
[TBL] [Abstract][Full Text] [Related]
17. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Souroullas GP; Jeck WR; Parker JS; Simon JM; Liu JY; Paulk J; Xiong J; Clark KS; Fedoriw Y; Qi J; Burd CE; Bradner JE; Sharpless NE
Nat Med; 2016 Jun; 22(6):632-40. PubMed ID: 27135738
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
19. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
20. DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A.
Licht JD
Trans Am Clin Climatol Assoc; 2018; 129():24-36. PubMed ID: 30166694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]